Literature DB >> 10090215

Heterogeneous changes in electrophysiologic properties in the paroxysmal and chronically fibrillating human atrium.

H F Tse1, C P Lau, G M Ayers.   

Abstract

INTRODUCTION: The regional changes in atrial electrophysiologic properties related to atrial fibrillation (AF) in patients with paroxysmal AF (PAF) and chronic AF (CAF) remain unclear. The purpose of this study was to investigate the regional changes in atrial electrophysiology in patients with AF. METHODS AND
RESULTS: We evaluated the atrial electrophysiology at different sites (high right atrium, low right atrium [LRA], and distal coronary sinus [DCS]) in 11 patients with CAF, 8 patients with PAF, and 10 controls. Patients with CAF had significantly prolonged interatrial conduction and corrected sinus node recovery time, and shortened atrial effective refractory period (ERP) with loss of rate-related adaptation in the DCS, but had paradoxic prolongation of atrial ERP in the LRA, as compared with patients with PAF and the controls. As a result, the spatial distribution of atrial ERP that was observed in the controls and in patients with PAF was reversed in patients with CAF, without an increase in the dispersion of atrial refractoriness. Patients with PAF showed intermediate changes in atrial conduction times and atrial refractoriness as compared with patients with CAF and controls.
CONCLUSION: There was a regional heterogeneity on the changes of atrial electrophysiology in different parts of the atrium, and the "normal" spatial distribution of atrial refractoriness was reversed in patients with CAF. The electrophysiologic changes observed in patients with PAF appear to behave as if in transition from the control state to CAF, suggesting progressive changes in atrial electrophysiologic properties.

Entities:  

Mesh:

Year:  1999        PMID: 10090215     DOI: 10.1111/j.1540-8167.1999.tb00653.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  8 in total

1.  The spatial dispersion of atrial refractoriness and atrial fibrillation vulnerability.

Authors:  F X Roithinger; M R Karch; P R Steiner; A SippensGroenewegen; M D Lesh
Journal:  J Interv Card Electrophysiol       Date:  1999-12       Impact factor: 1.900

2.  Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters.

Authors:  M Biffi; G Boriani; M Bartolotti; L Bacchi Reggiani; R Zannoli; A Branzi
Journal:  Heart       Date:  2002-05       Impact factor: 5.994

3.  Effect of verapamil on prevention of atrial fibrillation in patients implanted with an implantable atrial defibrillator.

Authors:  H F Tse; Q Wang; C M Yu; G M Ayers; C P Lau
Journal:  Clin Cardiol       Date:  2001-07       Impact factor: 2.882

Review 4.  Novel molecular targets for atrial fibrillation therapy.

Authors:  Dobromir Dobrev; Leif Carlsson; Stanley Nattel
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

5.  Post-operative atrial fibrillation is influenced by beta-blocker therapy but not by pre-operative atrial cellular electrophysiology.

Authors:  Antony J Workman; Davide Pau; Calum J Redpath; Gillian E Marshall; Julie A Russell; Kathleen A Kane; John Norrie; Andrew C Rankin
Journal:  J Cardiovasc Electrophysiol       Date:  2006-11

Review 6.  The role of action potential alternans in the initiation of atrial fibrillation in humans: a review and future directions.

Authors:  Michael R Franz; Sameer M Jamal; Sanjiv M Narayan
Journal:  Europace       Date:  2012-11       Impact factor: 5.214

7.  Prolonged PR interval predicts clinical recurrence of atrial fibrillation after catheter ablation.

Authors:  Junbeom Park; Tae-Hoon Kim; Jihei Sara Lee; Jin Kyu Park; Jae Sun Uhm; Boyoung Joung; Moon Hyoung Lee; Hui-Nam Pak
Journal:  J Am Heart Assoc       Date:  2014-10-07       Impact factor: 5.501

8.  Exploring Refractoriness as an Adjunctive Electrical Biomarker for Staging of Atrial Fibrillation.

Authors:  Lianne N van Staveren; Natasja M S de Groot
Journal:  J Am Heart Assoc       Date:  2020-11-26       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.